(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
|---|---|---|---|---|---|---|---|
| 2oiq | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus) | PK_Tyr_Ser-Thr | ||
| 3g5d | 1N1 | Dasatinib (DB01254) | Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus) | PK_Tyr_Ser-Thr | ||
| 4mxo | DB8 | Bosutinib (DB06616) | Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6l8l | 1E8 | Ibrutinib (DB09053) | Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus) | PK_Tyr_Ser-Thr | ||
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |